🔴 Moleculin Biotech is trading 5.25% down with no clear company-specific catalyst

Moleculin Biotech is trading at $0.57, down 5.25%, with no clear company-specific catalyst identified for the September 28 decline.

• Its September 25 announcement covered preclinical Annamycin findings presented at AACR, not a newly reported negative development.
• Renewed U.S.-Iran tensions lifted oil prices and bond yields as Wall Street futures fell, creating a risk-off backdrop that may have weighed on sentiment; evidence does not establish it as the direct cause.
• The premarket decline was also reported without a clear company-specific catalyst.